Kevin Bingle, MD
Family Medicine · Maumee, OHNPI 1538681812
Payments from drug & device makers
Across 142 payments — averaging $19.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$348
- Pfizer$316
- AstraZeneca$263
- AbbVie$236
- GSK$181
- Otsuka America Pharmaceutical, Inc.$179
- plus $1K from 27 others
What the payments were for
- Food & beverage$2,742100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $348 |
| Pfizer | 15 | $316 |
| AstraZeneca | 10 | $263 |
| AbbVie(2 entities) | 13 | $236 |
| GSK | 9 | $181 |
| Otsuka America Pharmaceutical, Inc. | 8 | $179 |
| Lilly USA, LLC | 7 | $121 |
| Lundbeck LLC | 5 | $105 |
| Exact Sciences | 5 | $90 |
| Amarin Pharma, Inc. | 5 | $85 |
| Johnson & Johnson | 5 | $83 |
| Abbott | 4 | $74 |
| Astellas Pharma US Inc | 3 | $72 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $62 |
| Kowa Pharmaceuticals America, Inc. | 1 | $53 |
| Boehringer Ingelheim | 2 | $49 |
| Dexcom, Inc. | 2 | $48 |
| Amgen | 3 | $44 |
| Dynavax Technologies Corporation | 2 | $44 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Phadia US Inc. | 2 | $32 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Shield Therapeutics Inc | 1 | $17 |
| VBI Vaccine (delaware) Inc. | 1 | $17 |
| Kaleo, Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Philips North America LLC | 1 | $15 |
| Merck | 1 | $15 |
| Corium, LLC | 1 | $13 |
| Almatica Pharma LLC | 1 | $12 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$2,742 in reported general payments places this provider in the 75th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 56 | $68,051 |
| EliquisApixaban | 60 | $65,273 |
| JardianceEmpagliflozin | 34 | $47,639 |
| JanuviaSitagliptin Phosphate | 33 | $32,440 |
| XareltoRivaroxaban | 19 | $27,311 |
| TrulicityDulaglutide | 20 | $26,907 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $16,856 |
| MounjaroTirzepatide | 14 | $15,356 |
| FarxigaDapagliflozin Propanediol | 11 | $13,916 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $9,300 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $5,222 |
| Testosterone | 12 | $4,239 |
| Atorvastatin Calcium | 323 | $3,526 |
| Omeprazole | 205 | $3,376 |
| Novolin 70-30Insulin Nph Hum/Reg Insulin Hm | 12 | $3,305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $316 | $68,11581 claims |
| Novo NordiskOzempic | $348 | $68,05156 claims |
| Boehringer IngelheimJardiance | $49 | $47,63934 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $121 | $42,26334 claims |
| MerckJanuvia | $15 | $32,44033 claims |
| Johnson & JohnsonXarelto | $83 | $27,31119 claims |
| GSKTrelegy Ellipta | $181 | $16,85617 claims |
| AstraZenecaFarxiga | $263 | $13,91611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Maumee
- Bradley EverlyMaumee$266K
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.